SEATTLE, June 27, 2013 /PRNewswire/ -- Adaptive Biotechnologies announced today that it has signed an agreement with Biogen Idec for the study of the immune repertoire and the search for immunological biomarkers in difficult to treat autoimmune diseases.
Under the collaboration, Adaptive's proprietary immune profiling assay, immunoSEQ, will be used to characterize the immune repertoire of patient samples with autoimmune disorders with high unmet medical needs. The immunoSEQ assay uses high throughput next-generation sequencing to characterize the repertoire of T and B cell receptors, which can be very useful to monitor the immune status of patients with autoimmune diseases and to assess the impact of treatments that impact or alter the immune system.
"We are delighted to collaborate with Biogen Idec to help further characterize the immune status of patients with autoimmune diseases who are often quite heterogeneous and therefore, difficult to treat without a more personalized approach," said Chad Robins, CEO and Founder of Adaptive Biotechnologies. "Partnering with Biogen Idec fits squarely with Adaptive's dual commitment to a deeper understanding of complex diseases as well as to finding better means to treat them."
About Adaptive Biotechnologies
Adaptive Biotechnologies Corporation (http://www.adaptivebiotech.com), headquartered in Seattle, WA, is pioneering the field of genomic immunology. The company's core competency is developing next generation sequencing assays that characterize the adaptive immune system, serving as a platform technology to the research and clinical communities as well as the biopharmaceutical industry. Adaptive operates a state-of-the-art high throughput centralized laboratory in Seattle that is CLIA certified and will be accepting clinical samples in 2013. Its flagship commercial product, immunoSEQ (http://www.immunoSEQ.com), uses a proprietary immune profiling assay to analyze T cells and B cells critical components of the adaptive immune system's defense against disease with unprecedented depth and specificity. In 2013, the company will introduce clonoSEQ (http://www.clonoseq.com), a clinical assay to measure and monitor minimal residual disease (MRD) in a range of blood-based cancers that is significantly more sensitive than today's most common tests. All of Adaptive Biotechnologies' assays are coupled with a cloud-computing infrastructure that simplifies the interpretation of massive quantities of data in a user-friendly interface.
SOURCE Adaptive Biotechnologies Corporation